Primer group, kit and detection system for thalassemia gene detection

By designing primer sets and a third-generation sequencing platform suitable for thalassemia gene detection, and combining them with an automated analysis process, the fragmentation and high cost of thalassemia gene typing in existing technologies have been solved, achieving efficient and accurate gene detection.

CN121472396APending Publication Date: 2026-02-06THE FIRST AFFILIATED HOSPITAL OF GUANGZHOU MEDICAL UNIV (GUANGZHOU RESPIRATORY CENT)
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202511542143.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-10-27
Publication Date
2026-02-06

AI Technical Summary

Technical Problem

Existing technologies struggle to achieve comprehensive, accurate, and efficient thalassemia genotyping. They suffer from targeting and fragmentation defects, fail to fully cover complex gene sequences, face challenges in multiple amplification balance and specificity, and fail to systematically integrate modified genes, resulting in high testing costs and a high risk of misdiagnosis.

Method used

A primer set for thalassemia gene detection was designed, covering core genes such as HBA2, HBA1, and HBB, as well as modified genes. Combined with a third-generation sequencing platform, it enables multiplex PCR amplification and single-base nanopore sequencing, and is equipped with an automated bioinformatics analysis workflow. It can detect point mutations, small insertions, small deletions, gene fusion mutations, and large fragment deletions.

Benefits of technology

It achieves comprehensive coverage of thalassemia genes in a single test, accurately distinguishes homologous regions, simultaneously detects multiple variant types, provides mutation phase analysis and modified gene information, lowers the analysis threshold, and improves detection efficiency and cost-effectiveness.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN121472396A_ABST
    Figure CN121472396A_ABST
Patent Text Reader

Abstract

The invention discloses a primer group, a kit and a detection system for thalassemia gene detection. In order to more comprehensively and accurately detect point mutation, small insertion, small deletion, gene fusion mutation, large fragment deletion and gene structure variation on a thalassemia core gene and a modified gene in single detection, the invention provides a thalassemia gene detection primer group and a kit. Based on third-generation sequencing platforms such as a single-base nanopore sequencing platform and the like, all point mutation, small insertion, small deletion and gene fusion mutation in the amplification range of the thalassemia core gene and the modified gene can be detected by utilizing the primer group or the kit; and 60 alpha large fragment deletion mutations, 60 beta large fragment deletion mutations and 7 gene structure variations. The method is beneficial to rapid and comprehensive screening of thalassemia, and is high in detection sensitivity and good in accuracy.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of gene testing service technology. More specifically, it relates to a primer set, reagent kit, and detection system for thalassemia gene detection. Background Technology

[0002] Thalassemia is an autosomal recessive hemolytic disease caused by a defect in the globin gene, leading to impaired synthesis of globin peptide chains. Clinically, patients with severe thalassemia require lifelong blood transfusions and iron chelation therapy, placing a heavy economic burden on their families and society. Population screening and prenatal diagnosis are crucial for the prevention and control of thalassemia, which heavily relies on accurate and comprehensive genetic testing technologies.

[0003] The molecular genetic diagnosis of thalassemia involves a series of key genes. Alpha-thalassemia is primarily caused by deletions or mutations in the HBA2 and HBA1 genes within the alpha-globin gene cluster. These deletions or loss of function are the root cause of hydrops fetalis syndrome (Hb Bart's) or hemoglobin H disease (HbH). β-thalassemia mainly originates from point mutations or small insertions in the HBB gene within the β-globin gene cluster. Although the delta chain encoded by the HBD gene is highly homologous to the β chain, mutations in it can lead to rare delta-β-thalassemia or affect hemoglobin A2 (HbA2) levels, the latter being an important indicator for screening β-thalassemia carriers. Sustained expression of fetal hemoglobin (HbF) can significantly alleviate the clinical symptoms of β-thalassemia. Therefore, promoter region variations of its encoding genes HBG1 and HBG2, as well as the functional status of key regulators such as BCL11A (a major transcriptional repressor) and the HBS1L-MYB region (a quantitative trait locus affecting erythropoiesis and HbF levels), have become central to phenotypic modification research and therapeutic target development. Furthermore, α-hemoglobin stabilizing protein (AHSP), as a molecular chaperone assisting in the proper folding of α-globin, may exacerbate ineffective hematopoiesis in β-thalassemia due to its defects. Mutations in KLF1, a core transcription factor in erythrocyte development, can lead to various phenotypes, including elevated HbF and rare thalassemia-like phenotypes.

[0004] Currently, the clinical molecular diagnosis of thalassemia faces significant technical bottlenecks, hindering the achievement of comprehensive, accurate, and efficient integrated genotyping. Existing molecular diagnostic systems for thalassemia suffer from core deficiencies of "targeting" and "fragmentation," with each conventional technique having its limitations. For example, Gap-PCR struggles to detect unknown deletions, reverse dot blot hybridization (RDB) cannot identify de novo point mutations, MLPA cannot accurately pinpoint deletion breakpoints, and Sanger sequencing and next-generation sequencing (NGS) cannot reliably distinguish between highly homologous HBA1 / HBA2 genes and lack the ability to recognize complex structural variations. This necessitates a multi-platform approach for complete genotyping, resulting in cumbersome, time-consuming, and costly processes. Furthermore, manual data integration is prone to introducing misdiagnosis and missed detection risks. In addition, current technologies fail to provide crucial mutation phase information, and their detection scope is typically limited to core genes, failing to systematically integrate modified genes, severely restricting the accurate analysis of complex cases.

[0005] Although third-generation sequencing technology, with its long read length and other characteristics, theoretically offers the possibility of solving the above-mentioned defects in one go, its practical application efficiency is highly dependent on optimized primer design, and existing third-generation sequencing solutions also face three major core challenges: (1) The challenge of specific amplification under complex gene sequences: Thalassemia-related genes (such as the HBA region) have the characteristics of high repetition, high GC content region and high sequence homology (such as HBA2 / HBA1>96%), which puts forward extremely high requirements for the specificity of primer design and experimental system.

[0006] (2) Challenges of balance and specificity in multiplex amplification: To achieve comprehensive detection, it is necessary to design multiplex PCR primer sets that cover multiple genes. The primer sets must avoid primer dimer generation and maintain balanced amplification efficiency among each target site. This is an extremely complex design and optimization process; otherwise, it will lead to uneven coverage and data waste.

[0007] (3) Adaptation requirements for sequencing platform characteristics: Primer design and experimental system must be deeply coupled with the characteristics of sequencing platform (such as nanopore sequencing) to produce amplification products with appropriate length, good integrity and low background noise. However, there is still no experience in this regard.

[0008] In summary, there is still an urgent need for a stable, efficient, specific primer set, reagent kit, and detection system that is balanced across all targets and compatible with third-generation sequencing platforms for the detection of thalassemia genes. Summary of the Invention

[0009] To address the shortcomings of the existing technologies, this invention provides a primer set, reagent kit, and detection system for thalassemia gene detection.

[0010] The first objective of this invention is to provide a primer set for the detection of thalassemia genes.

[0011] A second objective of this invention is to provide the application of the primer set in the preparation of products for detecting gene mutations in thalassemia.

[0012] A third objective of this invention is to provide a kit for thalassemia gene detection.

[0013] A fourth object of the present invention is to provide the use of the kit in the preparation of products for detecting gene mutations in thalassemia.

[0014] The fifth objective of this invention is to provide a detection system for thalassemia gene detection.

[0015] The above-mentioned objective of this invention is achieved through the following technical solution: To enable more comprehensive and accurate detection of point mutations, small insertions, small deletions, gene fusion mutations, large fragment deletions, and gene structural variations in thalassemia genes (including core thalassemia genes (HBA2, HBA1, HBB) and modified genes (HBD, HBG1, HBG2, AHSP, BCL11A, HBS1L-MYB, and KLF1)) in a single test, this invention, through design, testing, and redesign screening, has obtained a primer set for thalassemia gene detection. Simultaneously, this invention provides a kit and detection system for thalassemia gene detection based on the primer set.

[0016] This invention provides a primer set for thalassemia gene detection.

[0017] Specifically, the primer set contains 33 primers with nucleotide sequences as shown in SEQ ID NO:1 to SEQ ID NO:33; the thalassemia genes include HBA2, HBA1, HBB, HBD, HBG1, HBG2, BCL11A, HBS1L-MYB, AHSP, and KLF1 genes.

[0018] This invention seeks protection for the use of the primer set in the preparation of products for detecting gene mutations in thalassemia.

[0019] Specifically, the thalassemia gene mutations include all point mutations, small insertions, small deletions and gene fusion mutations within the amplification range of the primers contained in the primer set, as well as 60 large α deletion mutations, 60 large β deletion mutations and 7 gene structural variations; The 60 α-fragment deletion mutations are shown in the table below (Table 2 in the specification):

[0020] The 60 β-fragment deletion mutations are shown in the table below (Table 3 in the specification):

[0021] The seven gene structural variations are ααα anti3.7 , ααα anti4.2 , αααα anti3.7 , αααα anti4.2 , HKαα, anti-HKαα and αHKαα.

[0022] Specifically, the product is a product based on third-generation sequencing used to detect the thalassemia gene mutation.

[0023] In a specific embodiment of the present invention, the third-generation sequencing is single-base nanopore sequencing.

[0024] The present invention also provides a kit for thalassemia gene detection.

[0025] Specifically, the kit contains the primer set described above.

[0026] More specifically, the kit also contains reagents required for PCR reactions and reagents required for constructing sequencing libraries.

[0027] Specifically, the reagents required for constructing the sequencing library include a DNA repair and ligation reaction system, barcode adapter reagent, digestion reaction solution, universal primers, sequencing complex, library binding reaction solution, purification magnetic beads, sequencing reagents, chip cleaning reagents, and sequencing chip.

[0028] Optionally, the kit may also contain reagents required for the extraction of genomic DNA from the sample.

[0029] The present invention also claims protection for the use of the kit in the preparation of products for detecting gene mutations in thalassemia.

[0030] Specifically, the thalassemia gene mutations include all point mutations, small insertions, small deletions, and gene fusion mutations within the amplification range of the primers contained in the primer set, as well as the 60 α-fragment deletion mutations shown in Table 2 of the specification, the 60 β-fragment deletion mutations shown in Table 3 of the specification, and 7 gene structural variations; the 7 gene structural variations are ααα. anti3.7 , ααα anti4.2 , αααα anti3.7 , αααα anti4.2 , HKαα, anti-HKαα and αHKαα.

[0031] Specifically, the product is a product based on third-generation sequencing used to detect the thalassemia gene mutation.

[0032] The present invention also provides a detection system for thalassemia gene detection, including a sample processing module, a library construction and sequencing module, a bioinformatics analysis module, and a report generation module; The sample processing module contains genomic DNA extraction reagents, the detection primer set described in this invention, and reagents required for PCR reaction; the module is used to automatically extract genomic DNA from the sample to be tested and complete multiplex PCR amplification; The library construction and sequencing module contains the reagents and sequencer required for constructing a third-generation sequencing library; the module is used to complete the construction and sequencing of the amplification product into a third-generation sequencing library to obtain sequencing data. The bioinformatics analysis module contains a non-volatile storage medium storing computer programs; the module is used to identify various mutations within the detection range of the thalassemia gene and determine their phase relationships. The thalassemia gene mutations mentioned include all point mutations, small insertions, small deletions, and gene fusion mutations within the amplification range of the primers contained in the primer set, as well as the 60 α-fragment deletion mutations shown in Table 2 of the specification, the 60 β-fragment deletion mutations shown in Table 3 of the specification, and 7 gene structural variations; the 7 gene structural variations are ααα. anti3.7 , ααα anti4.2 , αααα anti3.7 , αααα anti4.2 , HKαα, anti-HKαα and αHKαα; The report production module is used to integrate the analysis results and generate clinical reports.

[0033] Beneficial effects: This invention provides a primer set, kit, and detection system capable of detecting all point mutations, small insertions, small deletions, and gene fusion mutations, as well as α-large deletion mutations, β-large deletion mutations, and gene structural variations within the primer amplification range designed for the thalassemia genes HBA2, HBA1, HBB, HBD, HBG1, HBG2, BCL11A, HBS1L-MYB, AHSP, and KLF1, in a single test. Compared with traditional molecular detection methods for thalassemia, the primer set, kit, or detection system described in this invention has the following advantages: (1) Seamless coverage of complex regions: It can accurately cross the high homology region of HBA2 / HBA1 genes, clearly distinguish and locate point mutations and deletion types, and effectively solve the problem of misjudgment caused by homologous recombination in traditional methods.

[0034] (2) Simultaneous detection of variant types: A single run can simultaneously detect all point mutations, small insertions, small deletions, and gene fusion mutations within the primer amplification range of the thalassemia genes described in the amplification range, and cover the 60 types of large α-fragment deletion mutations, 60 types of large β-fragment deletion mutations (such as Southeast Asian type, Thai type, etc. α-thalassemia deletion and HPFH and other deletion type β-thalassemia) and 7 types of α-gene structural variations, without the need for multiple technology platforms to run in parallel.

[0035] (3) Achieve mutation phase resolution: With the help of sequencing platforms, the variation information on a single chromosome can be directly read through long reads, which can accurately determine the cis-trans configuration of compound heterozygous mutations or multiple SNPs, providing crucial haplotype information for genetic counseling.

[0036] (4) Comprehensive integration of modified gene analysis: In addition to the core genes of thalassemia, this invention also incorporates the genotyping of thalassemia modified genes, such as BCL11A, HBS1L-MYB, AHSP and KLF1, into the same detection system, which can obtain information on primary mutations that cause thalassemia and secondary modified factors that affect the degree of clinical manifestations at one time, providing a more comprehensive genotype-phenotype association insight for clinical practice.

[0037] (5) Supporting automated analysis system: The present invention has developed an automated bioinformatics analysis process and system that can efficiently process long read data and automatically complete comparison, variant identification, phase determination, annotation and report generation, thereby reducing the analysis threshold.

[0038] (6) Optimized adaptation to single-base nanopore sequencing: The primer set described in this invention has been specially optimized to be deeply compatible with the long read length and high precision characteristics of the single-base nanopore sequencing platform, which effectively improves data utilization and detection cost-effectiveness. Attached Figure Description

[0039] Figure 1 Typical sequencing quality data obtained in accuracy testing.

[0040] Figure 2 This is a statistical chart showing the number of times a single-base nanopore sequencing chip was reused in sensitivity testing.

[0041] Figure 3 This is the sequencing diagram of the clinical sample S2 described in Example 3 of the present invention.

[0042] Figure 4 This is the sequencing diagram of clinical sample S4 described in Example 3 of the present invention.

[0043] Figure 5 This is the sequencing diagram of clinical sample S15 described in Example 3 of the present invention.

[0044] Figure 6This refers to haplotype phasing analysis results for clinical samples with phenotypic-genotypic discrepancies that cannot be explained by traditional detection methods.

[0045] Figure 7 BCL11A genotyping results for clinical samples with phenotype-genotype mismatches that cannot be explained by traditional detection methods.

[0046] Figure 8 The electrophoretic detection results are for the amplified products obtained in experimental groups 1-3. Detailed Implementation

[0047] The present invention will be further illustrated below with reference to specific embodiments, but the embodiments do not limit the present invention in any way. Unless otherwise specified, the reagents, methods, and equipment used in the present invention are conventional reagents, methods, and equipment in this technical field.

[0048] Unless otherwise specified, all reagents and materials used in the following examples are commercially available.

[0049] Example 1: Methods for obtaining and using primer sets and kits for thalassemia gene detection. 1. Obtaining the primer set for thalassemia gene detection To enable more comprehensive and accurate detection of point mutations, small insertions, small deletions, gene fusion mutations, large fragment deletions, and gene structural variations on the core genes and modified genes of thalassemia (including HBA2, HBA1, HBB, HBD, HBG1, HBG2, BCL11A, HBS1L-MYB, AHSP, and KLF1 genes, the sequences of which are derived from the NCBI database, with reference genome GRCh38.p14) in a single test, this invention, through design, testing, and redesign screening, has obtained a primer set for thalassemia gene detection (as shown in Table 1). Based on the single-base nanopore sequencing platform, using the primer set described in this invention, single-base nanopore long-read sequencing can detect all point mutations, small insertions, small deletions, and gene fusion mutations within the amplification range of primers designed for the core thalassemia gene and modified genes (almost covering all point mutations, small insertions, small deletions, and gene fusion mutations on the gene, as the detection range almost covers the entire gene), as well as 60 α-fragment deletion types (as shown in Table 2), 60 β-fragment deletion types (as shown in Table 3), and 7 gene structural variations (including ααα). anti3.7 , ααα anti4.2 , αααα anti3.7 , αααα anti4.2 , HKαα, anti-HKαα and αHKαα).

[0050] Table 1 Primer set used for thalassemia gene detection

[0051] The amplification products of the primers shown in Table 1 range from 9 kb to 15 kb in length, with some types corresponding to products ≤ 6 kb (such as the SEA type). Different combinations of primers shown in the table can detect different mutations. For example, HBA-F3 can be combined with HBA-R1 and HBA-R2 respectively; combined with HBA-R1, it can detect deletion types such as --BRIT and --MED I; combined with HBA2-R2, it can detect deletion types such as 21.9 kb deletion with 29 bp insertion and --SA.

[0052] Table 2. Types of detectable α-fragment deletion mutations

[0053] Table 3. Types of detectable large β deletion mutations

[0054] 2. Obtaining a kit for thalassemia gene testing Based on the obtained primer set, the present invention also provides a kit for thalassemia gene detection. In addition to the primer set shown in Table 1, the kit also contains sample genomic DNA extraction reagent, PCR reaction solution, library construction reagent, positive control and negative control.

[0055] In this embodiment, the sample genomic DNA extraction reagent is a nucleic acid extraction or purification reagent (magnetic bead method D-4801-BS type) extraction kit produced by Guangzhou Kaipu Pharmaceutical Technology Co., Ltd.; the PCR reaction solution is PrimeSTARGXL Premix Fast (Takara R053); and the library preparation reagent is a library preparation kit for the single-base nanopore sequencing platform from Jinshi Technology. The library preparation kit contains a DNA repair and ligation reaction system, barcode adapter reagent, digestion reaction solution, universal primers, sequencing complex, library binding reaction solution, purification magnetic beads, sequencing reagents, chip cleaning reagents, and a sequencing chip.

[0056] 3. Instructions for using the kit for thalassemia gene testing The present invention further provides, through optimization, a method for using the kit for thalassemia gene detection, namely, a method for detecting point mutations, small insertions, small deletions, gene fusion mutations, large fragment deletions, and gene structural variations on the thalassemia core gene and modified genes described in the present invention using the kit, the method comprising the following steps: S1. Extract genomic DNA from the sample to be tested; S2. Using the primer set shown in Table 1, perform multiplex PCR amplification of the genomic DNA obtained in S1 in a single-tube reaction system; S3. Construct a third-generation sequencing library based on the amplification products obtained in S2 and perform single-base nanopore sequencing to obtain long-read sequencing data; S4. Analyze the sequencing data obtained in S3, identify various variants within the detection range (i.e. primer amplification range) of the thalassemia core gene and modified gene, and determine their phase relationships; the variants include point mutations, small insertions, small deletions, gene fusion mutations, large fragment deletions, and gene structural variations.

[0057] When analyzing sequencing data, the core steps of the analysis method include haplotype phasing analysis to determine whether heterozygous mutations are located on the same chromosome (cis) or on two separate homologous chromosomes (trans).

[0058] In this embodiment, in S1, peripheral blood genomic DNA is extracted using a nucleic acid extraction or purification reagent (magnetic bead method D-4801-BS type) extraction kit produced by Guangzhou Kaipu Pharmaceutical Technology Co., Ltd., in conjunction with a fully automated nucleic acid extractor produced by Guangdong Kaipu Technology Manufacturing Co., Ltd.

[0059] In S2, the multiplex PCR amplification system used is shown in Table 4, and the multiplex PCR amplification program used is shown in Table 5. In the multiplex PCR amplification system, the working concentration of each primer in the primer set is 0.04 μM to 0.24 μM.

[0060] Table 4 Multiplex PCR amplification system

[0061] Table 5 Multiplex PCR Amplification Program

[0062] The bands of the multiplex PCR amplification products obtained by using the multiplex PCR amplification system and program described in this invention are clear, single (specific), and consistent in size with expectations. They are not diffuse and are bright, providing high-quality templates for subsequent sequencing analysis. Moreover, the coverage depth of each target site is balanced, which can be adapted to the technical characteristics of the third-generation sequencing platform and significantly improve the proportion of long fragment products and data utilization.

[0063] In S3, the library construction and sequencing complex preparation were performed using the dedicated library preparation kit for the single-base nanopore sequencing platform from Jinshi Technology, i.e., the universal sample preparation kit (nanopore sequencing). The process is as follows: Take 100–200 ng of purified amplification product and use the DNA library preparation reagent in the kit to perform DNA end repair and ligation on the sample. Add 1 μL of NEB Next FFPE DNA Repair Mix (NEB M6630), 1.5 μL of reaction solution 1 (Jinshi Technology 030.001.001-01), and 0.5 μL of barcode adapter (Jinshi Technology 032.001.001), then add water to bring the ligation system to 15 μL. Incubate the prepared ligation system at 20°C for 30 min, then at 65°C for 5 min. Subsequently, according to the kit instructions, mix the end repair and ligation products with different barcode tags, add 2 μL of reaction solution 2 (Jinshi Technology 030.001.001-01), and perform post-ligation treatment. Incubate at 37°C for 10 min, purify with 0.5× magnetic beads, and add 10 μL of... Dissolve in ddH2O; use the sequencing complex preparation reagent (Jinshi Technology 031.001.001) from the kit to mix the library with the nanopore complex and sequencing primers, then incubate at 27°C for 20 min. After purification with magnetic beads, a DNA library suitable for instrument sequencing is obtained. In S3, DNA sequencing was performed using the Jinshi Technology single-base nanopore sequencer to obtain long-read sequencing data. The process is as follows: Start the G-seq500 single-base nanopore sequencer, set up the experiment, and install the sequencing chip. Add 5–7 μL of sequencing DNA library to the sequencing reagent, mix well, and load it onto the sequencing instrument. Then click "Start Sequencing". After sequencing is complete, the FastQ sequencing file will be automatically imported into the bioinformatics analysis software. Then use the accompanying cleaning kit to clean the G-seq500 chip and the sequencer. Finally, remove the chip and turn off the instrument.

[0064] In S4, the FastQ sequencing file will be automatically imported into the bioinformatics analysis software after sequencing is completed. Enter the barcode information of the corresponding sample, click Start Analysis to output the results and clinical report.

[0065] If no specific conditions are given in the above steps, the operation or conditions of conventional experimental procedures in this field can be followed.

[0066] 4. Detection system for thalassemia gene testing Based on the primer set and kit described in this invention, this invention also provides a detection system for thalassemia gene detection, comprising the following modules: (1) Sample processing module: The module contains genomic DNA extraction reagent, primer set of the present invention and reagents required for PCR reaction, which are used to complete the automated extraction of genomic DNA from the sample to be tested and to complete multiplex PCR amplification using primer set of the present invention; (2) Library construction and sequencing module: The module contains reagents and sequencers required for constructing third-generation sequencing libraries, used to complete the construction of third-generation sequencing libraries and single-base nanopore sequencing of amplified products to obtain long-read sequencing data; (3) Bioinformatics analysis module: The module contains a non-volatile storage medium storing a computer program. The computer program can be used to perform bioinformatics analysis on the obtained sequencing data, realize all the analysis functions that can be realized in S4 of the above method, especially the haplotype phase analysis function, identify various variations within the detection range of the thalassemia core gene and modified gene and determine their phase relationship; the variations include point mutations, small insertions, small deletions, gene fusion mutations, large fragment deletions and gene structural variations; (4) Report production module: used to integrate analysis results and generate easy-to-understand clinical reports.

[0067] Example 2 Evaluation of reagent kit detection performance 1. Accuracy Test This invention uses the Oxford Nanopore Technologies (ONT) third-generation sequencing platform as a control and tests the detection accuracy of the kit described in Example 1 of this invention using 50 accuracy test samples (accuracy test samples S1 to S50). For sites with inconsistencies in the detection results, gold standard methods such as Sanger sequencing (point mutation) and MLPA (deletion or structural variation) were used for verification.

[0068] The results of the accuracy test are shown in Table 6. As can be seen from Table 6, the detection results of thalassemia mutations in 50 accuracy test samples using the kit described in Example 1 of this invention are consistent with the control (Oxford Nanopore Generation III Sequencing), with an accuracy rate of 100%.

[0069] Table 6. Detection Accuracy Test Results

[0070] Furthermore, typical sequencing quality data obtained in the accuracy test of this invention are as follows: Figure 1 As shown. By Figure 1 It can be seen that the method described in this paper has reached the clinically practical standard of Q30 (99.9%) accuracy of the original sequencing, providing a key technical foundation for the accuracy of the test results.

[0071] 2. Detection sensitivity test This invention uses 10 DNA samples with known genotypes as sensitivity test samples (Sensitivity test samples S1 to S10) to test the detection sensitivity of the kit described in Example 1 of this invention. During the test, four DNA concentration gradients were set: 0.5 ng / μL, 1 ng / μL, 120 ng / μL, and 130 ng / μL. Each concentration sample was tested 10 times, with the test repeated 3 times, and the results were recorded for each test.

[0072] The detection sensitivity test results are shown in Table 7. As shown in Table 7, the detection limit of the kit described in Example 1 of this invention is 0.5 ng / μL. Based on 10 tests achieving full detection, the detection range is 1–120 ng / μL. Within this concentration range, the kit described in this invention can obtain reliable sequencing results with uniform coverage, which can be effectively interpreted.

[0073] Table 7 Detection Sensitivity Test Results

[0074] Note: In the table, "+" indicates that the test results can be accurately interpreted. The more "+" signs there are, the more uniform the coverage and the higher the depth of the test results. "-" indicates that the depth of the test results is insufficient and cannot be interpreted.

[0075] Furthermore, in the sensitivity test of this invention, the statistical graph of the number of times the single-base nanopore sequencing chip was reused is shown below. Figure 2 As shown. By Figure 2 As can be seen, the method described in this invention can maintain stable sequencing performance even after 10 repeated sequencing runs, highlighting the core advantage of the method described in this invention in significantly reducing the cost of a single test.

[0076] Example 3: Actual Detection Effect Test 1. Clinical sample testing effectiveness test This invention tested 16 clinical samples (with informed consent from the patients) that had been previously tested using PCR+fluidized hybridization, Sanger sequencing, and MLPA technology. The results are shown in Table 8.

[0077] Table 8. Detection results of 16 clinical samples

[0078] As shown in Table 8, the kit and method described in this invention can detect various thalassemia variants, including but not limited to α-globin gene deletions (such as -- 2.4 -- SEA ), Triad (ααα) anti3.7 ), structural variations (HKαα), large fragment deletions of the β-globin gene, and point mutations, etc.

[0079] As an example, the present invention provides sequencing maps of the clinical samples S2, S4, and S15, as follows: Figures 3-5 As shown. The sequencing map of clinical sample S15 is shown below. Figure 5 It can be seen that the present invention detected two point mutations β in this sample. E and β CAP The sequencing results clearly show that these two point mutations are located on different chromosomes, namely β. E and β CAP This forms an inverse structure.

[0080] 2. Detection of clinical samples with phenotypic-genotypic discrepancies that cannot be explained by traditional testing methods. In addition, the present invention used the kit and method described in Example 1 to test a clinical sample whose mutation result obtained by conventional detection method (PCR + flow-through hybridization) did not match its clinical phenotype (sample information: HB: 101g / L, MCV: 82.7fl, MCH: 26.8pg, HbA: 74.4%, HbA2: 4.4%, HbF: 21.2%; patient informed consent).

[0081] The traditional detection method yielded a β result for the clinical sample. 41-42 With β 17 The present invention detected β in this clinical sample. 41-42 With β 17 The mutations were located on different chromosomes, and a heterozygous BCL11A:c.198C>A mutation was detected. The haplotype phasing analysis results were consistent with the BCL11A genotyping results as follows: Figure 6 and 7 As shown. Figure 6 The c.126_129delCTTT (β) of the HBB gene was clearly shown. 41-42 ) and c.52A>T(β) 17 The mutations are located on two different chromosomes (trans configuration), meaning that traditional detection methods cannot determine the cis-trans configuration of the two mutations, which is not conducive to genetic counseling. However, the kit and method described in this invention can detect them. Simultaneously, by Figure 7 It is known that the present invention detected a c.198C>A heterozygous modification mutation in the BCL11A gene, which can relieve the inhibition of the γ-globin gene, thereby explaining the clinical phenotype of persistent high expression of fetal hemoglobin (HbF) in patients.

[0082] Comparative Example 1 In contrast, this invention provides two primer sets that were eliminated during the research and development process, as shown in Tables 9 and 10, respectively. The primers shown in Table 9 were obtained by redesigning or adjusting the primers obtained in the early stages, while the primers shown in Table 10 were designed and screened according to conventional primer design principles.

[0083] Table 9 Comparison Primer Set 1

[0084] Table 10 Comparison Primer Set 2

[0085] This invention uses 12 samples with known genotypes as test samples. PCR amplification was performed under the same conditions (amplification system and procedure as in Example 1) using Tables 1, 9 and 10 respectively (referred to as experimental groups 1, 2 and 3). 1 μL of amplification product was detected by 1% agarose gel electrophoresis. The remaining products were used to construct libraries and sequenced according to the method described in Example 1 to evaluate the specificity and uniformity of the amplification products.

[0086] The electrophoresis results of the products obtained by multiplex PCR amplification using the primer sets shown in Tables 1, 9, and 10 are as follows: Figure 8 As shown. By Figure 8 It can be seen that the bands of the products obtained from Experimental Group 1 are clear, uniform, and of the expected size, with no extraneous bands; some products amplified from Experimental Group 2 show banding, with obvious non-specific bands and primer dimers; the products amplified from Experimental Group 3 show obvious banding, and most samples have no amplified bands, indicating extremely unstable amplification. Further analysis of the sequencing results shows that the sequencing bands of Experimental Group 1 are uniform and the results can be clearly interpreted; the sequencing bands of Experimental Group 2 are uneven, and some samples failed to amplify the HBB target due to SNP interference; the sequencing bands of Experimental Group 3 are uneven, and some samples have only a few bands, making them completely uninterpretable. These results indicate that the primer set shown in Table 1 of this invention is significantly superior to the comparative primer set in terms of specificity and robustness.

[0087] The above embodiments are preferred embodiments of the present invention, but the embodiments of the present invention are not limited to the above embodiments. Any changes, modifications, substitutions, combinations, or simplifications made without departing from the spirit and principle of the present invention shall be considered equivalent substitutions and shall be included within the protection scope of the present invention.

Claims

1. A primer set for thalassemia gene detection, characterized in that, The thalassemia genes include HBA2, HBA1, HBB, HBD, HBG1, HBG2, BCL11A, HBS1L-MYB, AHSP, and KLF1 genes; the primer set contains 33 primers with nucleotide sequences as shown in SEQ ID NO:1 to SEQ ID NO:

33.

2. The use of the primer set according to claim 1 in the preparation of a product for detecting thalassemia gene mutations, characterized in that, The thalassemia gene mutations include all point mutations, small insertions, small deletions, and gene fusion mutations within the amplification range of the primers contained in the primer set, as well as 60 large α deletion mutations, 60 large β deletion mutations, and 7 gene structural variations. The 60 α-large fragment deletion mutations are shown in the table below: ; The 60 β-large fragment deletion mutations are shown in the table below: ; The 7 kinds of gene structural variations are ααα anti3.7 , ααα anti4.2 , αααα anti3.7 , αααα anti4.2 , HKαα, anti-HKαα and αHKαα.

3. The application according to claim 2, characterized in that, The product is based on third-generation sequencing for detecting the thalassemia gene mutation.

4. A kit for thalassemia gene detection, characterized in that, The kit contains the primer set as described in claim 1.

5. The reagent kit according to claim 4, characterized in that, The kit also contains reagents required for PCR reaction and reagents required for constructing sequencing libraries.

6. The reagent kit according to claim 5, characterized in that, The kit also contains reagents required for the extraction of genomic DNA from the sample.

7. The reagent kit according to claim 5, characterized in that, The reagents required for constructing the sequencing library include a DNA repair and ligation reaction system, barcode adapter reagent, digestion reaction solution, universal primers, sequencing complex, library binding reaction solution, purification magnetic beads, sequencing reagents, chip cleaning reagents, and sequencing chip.

8. The use of the kit according to any one of claims 4 to 7 in the preparation of a product for detecting the thalassemia gene mutation as described in claim 2.

9. The application according to claim 8, characterized in that, The product is based on third-generation sequencing for detecting the thalassemia gene mutation.

10. A detection system for thalassemia gene detection, characterized in that, It includes a sample processing module, a library construction and sequencing module, a bioinformatics analysis module, and a report generation module; The sample processing module contains genomic DNA extraction reagents, the detection primer set as described in claim 1, and reagents required for PCR reaction; the module is used to automatically extract genomic DNA from the sample to be tested and complete multiplex PCR amplification; The library construction and sequencing module contains the reagents and sequencer required for constructing a third-generation sequencing library; the module is used to complete the construction and sequencing of the amplification product into a third-generation sequencing library to obtain sequencing data. The bioinformatics analysis module contains a non-volatile storage medium storing a computer program; the module is used to identify the thalassemia gene mutation described in claim 2 and determine its phase relationship; The report production module is used to integrate the analysis results and generate clinical reports.